Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Precipio Inc is a diagnostics & research business based in the US. Precipio shares (PRPO) are listed on the NASDAQ and all prices are listed in US Dollars. Precipio employs 55 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $1.11 |
|---|---|
| 52-week range | $0.91 - $4.17 |
| 50-day moving average | $1.10 |
| 200-day moving average | $1.63 |
| Wall St. target price | $4.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.52 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.11 from 2022-07-01
| 1 week (2022-06-28) | -2.63% |
|---|---|
| 1 month (2022-06-06) | -3.48% |
| 3 months (2022-04-06) | -19.86% |
| 6 months (2022-01-06) | -29.30% |
| 1 year (2021-07-06) | -68.10% |
|---|---|
| 2 years (2020-07-06) | -15.27% |
| 3 years (2019-07-05) | 3.4 |
| 5 years (2017-07-05) | 20.1 |
| Revenue TTM | $9.5 million |
|---|---|
| Gross profit TTM | $2.4 million |
| Return on assets TTM | -31.73% |
| Return on equity TTM | -63.3% |
| Profit margin | -123.18% |
| Book value | $0.98 |
| Market capitalisation | $25.2 million |
TTM: trailing 12 months
We're not expecting Precipio to pay a dividend over the next 12 months.
Precipio's shares were split on a 1:15 basis on 28 April 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Precipio shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Precipio shares which in turn could have impacted Precipio's share price.
Over the last 12 months, Precipio's shares have ranged in value from as little as $0.91 up to $4.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Precipio's is 2.2721. This would suggest that Precipio's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Precipio, Inc. , a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.